Introduction | Published:

Signalling in cancer

Nature volume 441, page 423 (25 May 2006) | Download Citation


The past 30 years have led from the discovery of the first cancer-causing gene, or ‘oncogene’, to the emergence of a new generation of cancer therapies — those targeted at specific signalling molecules.

The signalling pathways controlling cell growth and differentiation are almost invariably altered in cancer. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. The reviews in this Insight discuss the molecular circuitry regulating several key cellular processes, and illustrate how defining the signalling mechanisms is aiding the development of therapies.

Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-κB transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signalling pathways; exploring their functional contributions has just begun.

Evaluating signalling molecules as drug targets is important for prioritizing research, even though we cannot predict the success of drugs in the clinic. Still, with several inhibitors of signalling molecules now approved for clinical use, and more in the pipeline, there is reason to celebrate 30 years of oncogene research. We hope these reviews provide a glimpse of recent excitements. Thanks are due to the authors for their contributions and to reviewers for their input.

We are pleased to acknowledge the financial support of Genentech and Pfizer in producing this Insight. As always, Nature carries sole responsibility for editorial content and peer review.

Author information


  1. Senior Editor

    • Alex Eccleston
  2. Chief Biology Editor

    • Ritu Dhand


  1. Search for Alex Eccleston in:

  2. Search for Ritu Dhand in:

About this article

Publication history



Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing